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Objective: Maternal autoantibodies are a risk factor for impaired brain development in offspring. Antibodies (ABs)
against the NR1 (GluN1) subunit of the N-methyl-D-aspartate receptor (NMDAR) are among the most frequently diag-
nosed anti-neuronal surface ABs, yet little is known about effects on fetal development during pregnancy.
Methods: We established a murine model of in utero exposure to human recombinant NR1 and isotype-matched non-
reactive control ABs. Pregnant C57BL/6J mice were intraperitoneally injected on embryonic days 13 and 17 each with
240μg of human monoclonal ABs. Offspring were investigated for acute and chronic effects on NMDAR function, brain
development, and behavior.
Results: Transferred NR1 ABs enriched in the fetus and bound to synaptic structures in the fetal brain. Density of
NMDAR was considerably reduced (up to −49.2%) and electrophysiological properties were altered, reflected by
decreased amplitudes of spontaneous excitatory postsynaptic currents in young neonates (−34.4%). NR1 AB-treated
animals displayed increased early postnatal mortality (+27.2%), impaired neurodevelopmental reflexes, altered blood
pH, and reduced bodyweight. During adolescence and adulthood, animals showed hyperactivity (+27.8% median activ-
ity over 14 days), lower anxiety, and impaired sensorimotor gating. NR1 ABs caused long-lasting neuropathological
effects also in aged mice (10 months), such as reduced volumes of cerebellum, midbrain, and brainstem.
Interpretation: The data collectively support a model in which asymptomatic mothers can harbor low-level pathogenic
human NR1 ABs that are diaplacentally transferred, causing neurotoxic effects on neonatal development. Thus, AB-
mediated network changes may represent a potentially treatable neurodevelopmental congenital brain disorder con-
tributing to lifelong neuropsychiatric morbidity in affected children.
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Proper fetal development in mammals requires complexmechanisms regulated from both fetus and mother.
One maternal immune mechanism to protect the fetus is
passive immunity, where maternal immunoglobulin G
(IgG) is transferred via neonatal Fc receptors (FcRn).1
Transfer of maternal antibodies (ABs) in humans starts
from gestational week 13 in the second trimester,2 when
the fetal blood–brain barrier (BBB) is still permeable,3 cre-
ating a critical window for potentially harmful anti-
neuronal ABs to compromise fetal brain development.
Maternal immune activation including such ABs may
therefore influence the etiology of neurodevelopmental
disorders, including autism spectrum disorders (ASD),
learning disabilities, and schizophrenia.4,5
Murine models of gestational transfer of maternal
ABs have already revealed deleterious effects of some anti-
neuronal ABs, for example, anti-NR2B (GluN2B),6 anti–
fetal brain ABs from mothers of children with ASD,7,8
and anti-Caspr2 ABs.9,10 So far, little is known about
maternal ABs against the NR1 (GluN1) subunit of the N-
methyl-D-aspartate receptor (NMDAR), although it is
among the most frequent anti-neuronal ABs in clinically
asymptomatic individuals, with an IgG seroprevalence of
1%.11,12 This creates a considerable subgroup of pregnan-
cies in which NR1 ABs can be diaplacentally transferred.
A pathogenic role for impairment of fetal brain develop-
ment by such ABs seems possible for several reasons. First,
monoclonal human NR1 ABs cloned from anti-NMDAR
encephalitis patients were directly pathogenic by dis-
rupting synaptic NMDAR currents.13 Second, in vitro
and in vivo studies in adult animals demonstrated human
NR1 AB-mediated internalization of NMDARs, resulting
in NMDAR hypofunction.14–16 Third, during fetal brain
development, NMDARs are crucial for proper axonal17
and dendritic growth,18 neuronal survival,19 and gluta-
matergic synaptic transmission at early stages.20 Fourth,
animal models of NMDAR hypofunction during neuro-
development, induced by either transient NMDAR block-
age21 or NR1 mutations,22 were characterized by major
developmental deficits, for example, growth retardation
and impaired cognitive functions.
We therefore hypothesized that maternally trans-
ferred NR1 ABs can cause fetal NMDAR hypofunction,
leading to impaired brain development and sustained defi-
cits persisting into childhood and possibly adulthood. If
verified, this could have far-reaching clinical implications,
including therapeutic options to prevent developmental
brain abnormalities and lifelong psychiatric morbidity in
affected children. Hence, we established a mouse model of
gestational transfer of human monoclonal NR1 ABs and
determined effects on NMDAR function, brain develop-
ment, and behavior in the offspring.
Materials and Methods
Animal Experiments
Animal experiments were carried out in accordance with the
ARRIVE guidelines, the EU directive (2010/63/EU) for animal
experiments, and were approved by the local ethics committee
for Animal Welfare (LaGeSO, Berlin, G0175/15).
At gestational days E13 and E17, 8- to 10-week-old preg-
nant C57BL/6J mice were either not treated (n = 6) or injected
intraperitoneally with 240μg human monoclonal IgG1 ABs each
(nonreactive control clone: #mGo53 [n = 40; CTL], high-
affinity NR1-reactive [amino-terminal domain] IgG1 clone:
#003-102 [n = 47; NR1])13,23,24 in sterile phosphate-buffered
saline (PBS). Further controls included identical amounts of
monoclonal IgG1 ABs against glial fibrillary acidic protein
(GFAP; clone: #011-11613 [n = 15]) and human immunoglobu-
lins (intravenous immunoglobulin [IVIG]; Grifols, Barcelona,
Spain [n = 15]). AB amounts were 10- to >100-fold lower than
in comparable passive immunization studies25,26 and resulted in
maternal serum NR1 AB levels of 1:100 to 1:320 in routine cell-
based assays. Animals were sacrificed as indicated in Figure 1.
Offspring were housed in treatment-mixed groups of 2 to 5 mice
of both sexes.
Production of Human Monoclonal ABs
Recombinant human monoclonal NR1-reactive IgG1 ABs
(clones #003-102 and #007-168) were generated from 2 female
patients with acute NMDAR encephalitis and produced together
with a nonreactive human monoclonal isotype-matched ABs
(#mGo53) and an anti-GFAP ABs (#011-116) as described pre-
viously.13,27 All ABs were IgG1; these cross the human placenta
and murine yolk sac with highest efficiency of all IgG
subclasses.28,29
Fetal AB Distribution
Embryos were harvested at E19, and whole embryo sections were
methanol-fixed and stained with rat anti-CD31 (1:150; BD Bio-
sciences, Franklin Lakes, NJ; #55370), rabbit anti-VGLUT1
(1:500; Synaptic Systems, Göttingen, Germany; #135303), and
rabbit-anti-NR1 (1:250; Merck, Darmstadt, Germany;
#AB9864). Secondary ABs included goat anti-human IgG-488
(1:1,000; Dianova, Hamburg, Germany; #109-095-003), goat
anti-rabbit-568, and goat anti-rat-568 (1:1,000; Life Technolo-
gies, Carlsbad, CA; #A11036, #A11077).
Serum AB Kinetics
Trunk blood from postnatal day (P) 0, P7, P10, and P14 pups
and respective dams was taken by decapitation, and human AB
levels were determined using a commercial antihuman IgG
enzyme-linked immunosorbent assay (ELISA; Mabtech, Nacka
Strand, Sweden).
IgG Extraction from Mouse Brain
Brain-bound IgG in immunized pups was extracted from whole
unperfused brains at P0 and P7 by an acid-based method
adapted from a previous protocol.15 Brains from P0/P7 pups
(~100/200mg) were homogenized in 6/10ml PBS with
November 2019 657
Jurek et al: maternal NMDAR antibodies
proteinase inhibitors (PBS-PI; Roche, Basel, Switzerland; cOm-
plete ethylenediaminetetraacetic acid [EDTA]-free tablets). Six
milliliters each were centrifuged, and the pellet was washed
3 times with 1ml PBS-PI to eliminate unbound IgG located in
blood vessels. For extraction of bound IgG, the pellet was dis-
solved for 5 minutes in 258μl 0.1M Na-citrate buffer (pH 2.7)
and centrifuged, and the supernatant was neutralized with 52μl
1.5M Tris (pH 8.8). Supernatant of the last wash (with 0.3ml)
was analyzed as pre-extraction fraction to exclude residual free
human IgG in the extract.
ELISA Quantification of Human NR1 ABs in Brain
Extracts
Concentration of recombinant human NR1 AB #003-102 in
brain extracts was determined in 96-well plates coated overnight
at 4C with donkey anti-rabbit IgG (20μg/ml, Dianova,
#711-005-152). After blocking with 2% bovine serum albumin
(BSA) in PBS/0.05% Tween-20 (PBS/T) at room temperature
(RT), cell culture supernatants of HEK293 cells that expressed
the amino-terminal domain (amino acids 1–400) of human NR1
fused to rabbit Fc were applied. Mouse brain extracts were
FIGURE 1: Experimental design and characterization of transfer of antibodies (ABs) in a gestational mouse model of maternal
NR1 ABs. (A) Experimental design for characterization of AB transfer and neonatal development at different time points
(n = pups; litters in parentheses) of control (CTL)/NR1/untreated dams. Blue = control, red = NR1, gray = untreated. (B, C)
Human recombinant monoclonal NR1 ABs used for this study showed the typical staining on murine brain sections, for example,
granular cells in cerebellum (B), and on NR1-transfected HEK cells (C). (D, E) The nonreactive human control ABs used
throughout this study did not bind NR1-expressing HEK cells (D) or brain tissue (E). (F) Injected human ABs were transferred into
the neonatal circulation with the highest concentrations at postnatal day (P) 0 for CTL and at P7 for NR1 AB-treated offspring,
with declining level afterward. (G) AB injections into dams starting only postnatally (P0 and P3) resulted in high levels of neonatal
ABs in both groups (P7), confirming that IgG ABs were also sufficiently transferred via breast milk. (H) Western blot (cropped) of
neonatal brains detected human IgG in both CTL and NR1 AB-treated animals (960μg per dam; 480μg;  = untreated; p.n. =
postnatal injection [480μg]). (I) Enzyme-linked immunosorbent assay quantification of NR1-specific ABs in brain IgG extracts
revealed increasing levels of brain-bound IgG from P0 (mean = 10.7ng) to P7 (mean = 37.4ng) in the NR1 group. (J, K) Brain IgG
extracts from NR1 AB-immunized neonates (P0) retained their binding capability to NR1 (J), whereas extracted IgG from the CTL
group did not show any binding (K). (L, N) CTL ABs distributed diffusely in the fetal brain (L), mainly around blood vessels (N,
arrowheads). (M, O) In contrast, NR1 ABs colocalized with punctate presynaptic VGLUT1 clusters (M, some clusters depicted with
arrows), mainly outside vessels in the brain parenchyma (O). Inserts show the area of the micrograph in the hippocampus (L–O).
Scale bars: B, E, 100μm, C, D, J, K, 20μm; L–O, 100μm. E = embryonic day; EPhys = electrophysiology; hum = human;
MRI = magnetic resonance imaging; NMDAR = N-methyl-D-aspartate receptor; rb = rabbit.
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diluted 1:25/1:100 in 0.4% BSA-PBS/T and added in dupli-
cates. Plates were washed with PBS/T and incubated with horse-
radish peroxidase (HRP)-conjugated donkey anti-human IgG
(1:5,000, Dianova, #709-035-149). After washing, HRP activity
was measured using 1-Step Ultra TMB-ELISA substrate
(Thermo Fisher Scientific, Waltham, MA). The concentrations
of #003-102 in the extracts were deduced from a calibration
curve generated with purified #003-102.
NR1-Specific Cell-Based Assay
NR1-transfected HEK cells were grown on coverslips, methanol-
fixed, blocked for 30 minutes, incubated overnight with murine
sera or IgG extracted from neonatal brains, and visualized as
described.13
Quantification of NR1 Protein, GluR1, and
Human IgG with Western Blots
Synaptosomal fractions were prepared from P0 pups with Syn-
PER (Life Technologies, #87793). For membrane and total
fractions, brains from P0 and P7 mice were homogenized in
10 volumes of homogenization buffer (0.32M sucrose, 10mM
hydroxyethylpiperazine ethane sulfonic acid [HEPES] pH 7.4,
2mM EDTA) and centrifuged at 1,000 × g for 10 minutes to
remove nuclear fraction. An aliquot of supernatant was kept as
total fraction. The remainder was centrifuged at 10,000 × g for
15 minutes, and supernatant was centrifuged at 100,000 × g for
60 minutes. Pellets from P0 and P7 pups were resuspended in
100 and 300μl sample buffer, respectively. CTL and NR1 AB-
treated samples were loaded on 8% acrylamide gels, transferred
via TurboBlot (Bio-Rad Laboratories, Hercules, CA) onto nitro-
cellulose, blocked, stained with rabbit-anti-NR1 (1:1,000,
Merck, #AB9864) or rabbit anti-GluR1 (1:8,000; Millipore,
Billerica, MA; #AB1504), and incubated with goat anti-rabbit
IgG-HRP (1:6,000; Vector Laboratories, Burlingame, CA; #PI-
1000). Membranes were developed with Western Lightning
(PerkinElmer, Waltham, MA). Consecutive incubation was car-
ried out with primary ABs for reference proteins (synaptosomal
and total cell fraction: mouse anti-mortalin, 1:5,000, NeuroMab
[Davis, CA], #75-217; membrane fraction: rabbit anti–β-actin,
1:3,000, Sigma-Aldrich [St Louis, MO], #A5060) and respective
secondary ABs.
Quantification of NR1 Protein Expression with
Immunohistochemistry
NMDAR clusters were detected with human monoclonal AB
clone #007-168. To exclude that this monoclonal "detection
AB" competes with the "treatment AB" (#003-102) for the same
epitope, 1mg of each AB was labeled with 8.4μl CruzFluor
488 succinimidylester (10mg/ml; Santa Cruz Biotechnology,
Santa Cruz, CA; #sc-362617). Murine brain sections were incu-
bated with a fixed concentration of labeled AB plus increasing
concentrations of either the identical unlabeled AB, the other AB
(competition assay), or a control AB (Homer-1, Synaptic Sys-
tems, #160004). For NR1 cluster analysis, brain sections were
incubated for 48 hours at 4C with Homer-1 (1:200) and
#007-168-Biotin (biotinylation kit, Thermo Fisher Scientific,
#QE217779, 15μg/ml), followed by goat anti–guinea pig-568
(Invitrogen, Carlsbad, CA; #A-11075) and streptavidin-488
(Invitrogen, #A-32360). Two pictures from the CA3 region were
taken from 3 individuals of ≥3 litters. Homer-1–positive synaptic
sites were marked manually, and fluorescence intensities for
human NR1 AB #007-168 were calculated automatically for
each marked site and corrected for background fluorescence.
Overlapping puncta of Homer-1 and human NR1 were counted
and displayed as ratio of colocalized to synaptic puncta.
Electrophysiological Recordings
Horizontal hippocampal vibratome slices (350μm) from P0 or
P7 pups of CTL and NR1 AB-immunized dams were transferred
to a submerged holding chamber and stored in artificial cerebro-
spinal fluid (in mM: 129 NaCl, 1.25 NaH2PO4, 1.6 CaCl2, 3.0
KCl, 1.8 MgSO4, 21 NaHCO3, 10 glucose) at 32 to 35C for
30 minutes, followed by RT until recording. Whole-cell patch
clamp recordings on CA1 pyramidal neurons were performed
with borosilicate pipettes (1.5mm outer diameter) filled with
internal solution containing (in mM) 125 CsCl, 2 Mg2Cl,
10 HEPES, 2 ethyleneglycoltetraacetic acid, 2 Na2ATP, 0.3
NaGTP. Access resistance did not exceed 20MΩ and varied less
than 20%. Signals were low-pass filtered at 2kHz and sampled at
10kHz. Spontaneous excitatory postsynaptic currents (sEPSCs)
were recorded at −70mV for at least 4 minutes. To avoid dep-
olarizing γ-aminobutyric acid (GABA) currents, GABAA-R
antagonist SR-95531 was applied (1μM; Tocris Bioscience, Bris-
tol, UK).
Determination of Blood pH
P0 pups from CTL and NR1 AB-treated animals were decapi-
tated, and trunk blood was mixed with 2 volumes of heparinized
NaCl to reach the minimal volume required for analysis with an
ABL-800 system (Radiometer, Brønshøj, Denmark).
Measurements of Activity
Transponders were implanted into offspring at 12 to 14 weeks.
Activity was tracked for 14 days with a Social Activity Monitor-
ing system (PhenoSys, Berlin, Germany) based on an ID-Grid
sensor plate recording individual spatiotemporal information.
Magnetic Resonance Imaging–Based
Determination of Brain Volume
Magnetic resonance imaging (MRI) was performed on P0 pups
and adult mice using a 7T small animal scanner (7T BioSpec
+1H-Cryoprobe; Bruker, Karlsruhe, Germany). Animals were
euthanized using isoflurane. Volumes of P0 animals were
assessed using a high-resolution morphological T2-weighed
TurboRARE sequence (repetition time/echo time = 4,000/34.5
milliseconds, 10 averages, rapid acquisition with relaxation
enhancement [RARE] factor = 8, 36 coronal slices per 0.25mm,
field of view = 12.8 × 12.8mm2, matrix = 170 × 170, in-plane
resolution = 75 × 75μm2, scan time = 14 minutes). Volumetry
was performed using Analyze 10.0 software (AnalyzeDirect,
Overland Park, KS). For adult mice (repetition time/echo
time = 4,250/33 milliseconds, 2 averages, RARE factor = 8,
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40 coronal slices per 0.40mm, field of view = 19.2 × 19.2 mm2,
matrix = 192 × 192, in-plane resolution = 100 × 100μm2, scan
time = 3 minutes 24 seconds), volumetry was performed auto-
matically using the MATLAB (MathWorks, Natick, MA) tool-
box ANTX to nonlinearly register magnetic resonance images to
the Allen brain atlas.30
Neurodevelopmental Scoring
Neonates were scored from days P3 to P56 based on established
protocols.31 The cutoff for surface righting reflex, cliff avoidance,
and negative geotaxis reflex was 30 seconds.
Behavioral Assessment
A modified SHIRPA test to identify general abnormalities32
showed a normal phenotype in all offspring prior to behavioral
assessment.
Three-Chamber Test (Sociability). After 10 minutes of
habituation to a 3-chambered arena for 6-week-old mice, an
empty cage and a cage containing an unfamiliar C57BL/6J
mouse (same sex) were placed in opposite side chambers.
The location of cages was systematically alternated between
animals. The number of times mice entered the chambers
and came close to the cages were recorded by the video
tracking system Viewer-3 (Biobserve, Bonn, Germany).
Barnes Maze. Seven-week-old mice were tested for learn-
ing and memory in a Barnes maze. They were trained for
4 days on a white platform to find a hidden escape box
under 1 of 20 holes. Orientation cues were placed around
the platform on the wall. Behavior and distance traveled
into the 4 quadrants were recorded with Viewer-3. Cutoff
was 180 seconds during training (4 trials every day for
4 days) and 90 seconds during testing (days 5 + 12, mem-
ory recall during 90 seconds).
Elevated Plus Maze. Eight-week-old mice on a white
polyvinyl chloride (50 × 50 × 53cm) elevated plus maze
with 2 open arms and 2 closed arms explored for
5 minutes, then activity was tracked using Viewer-3.
Prepulse Inhibition. Each test session in 9-week-old mice
consisted of 5 trial types according to established proto-
cols33: white noise (N56dB), acoustic startle (P120dB,
40 milliseconds), and 3 prepulse acoustic startle trials
(PP69dB, PP73dB, and PP81dB for 20 milliseconds,
100 milliseconds before acoustic startle of P120dB for
40 milliseconds). Each session started with 10 minutes of
acclimation, then 5 acoustic startle trials (P120dB), followed
by 10 blocks of the 5 prepulse trials (PP69dB–P120dB,
PP73dB–P120dB, PP81dB–P120dB) in pseudorandom
order and another 5 acoustic startle trials (P120dB). Inter-
trial intervals ranged between 12 and 30 seconds.
Home Cage Scan. Natural behaviors in the home cage of
freely moving mice were determined over 24 hours using
HomeCageScan software (CleverSys, Reston, VA), including
durations of grooming, twitching (indicator for repetitive
behavior), consumption (eating and drinking), and sleeping.
Nest Construction Test. Nestlets (5 × 5cm squares of
pressed white cotton) were placed in the cage on 2 consec-
utive days, and the nest was scored the next day for com-
plexity according to established protocols.34 The
remaining intact nestlet material was weighed.
Flow Cytometry–Based Quantification of NR1
Reactivity in Human Maternal Sera
Serum from 120 healthy mothers of children with psychiatric dis-
orders (MCPD) and 105 serum samples from healthy control
mothers of unaffected children (CTLM) were collected at the
Vivantes Department for Child and Adolescent Psychiatry, Berlin-
Friedrichshain, Germany. NR1 autoreactivity was quantified in a
flow cytometry–based approach using live HEK cells over-
expressing native human NR1 protein as described previously.23
Methods to Prevent Bias
Pregnant dams were randomly assigned for injection. After weaning,
mice of both treatment groups were mixed-housed. Within all exper-
iments, animals or samples were used in an alternating manner. The
investigator was blinded to group allocation and analysis for MRI,
electrophysiology, and NR1-positive cluster quantification. For
behavioral paradigms, sample size was determined by publicly avail-
able datasets, extracted numeric data by the use of PlotDigitizer
(http://plotdigitizer.sourceforge.net/), and subsequent a priori power
analysis using G*Power (http://www.gpower.hhu.de/).
Statistical Analysis
Statistical analyses were performed with Prism 7 (GraphPad Soft-
ware, San Diego, CA) and R (https://www.r-project.org/). Data
are presented as scatterplots with mean  standard deviation or
median with 95% confidence interval. Statistical analyses included
t test, analysis of variance (ANOVA), and repeated measurement
ANOVA following Holm–Sidak or Tukey multiple comparison
test. Mann–Whitney and Kruskal–Wallis tests were used for non-
parametric data, followed by Dunn multiple comparison test.
Wilcoxon test was used to compare total activity of animals,
1-sided Fisher exact test for frequency distribution, and Kaplan–
Meier log-rank test for survival with Bonferroni correction;
p < 0.05 was considered statistically significant.
Results
Human NR1 ABs Were Diaplacentally
Transferred and Bound to Synaptic Structures
within the Neonatal Brain
Human monoclonal recombinant NR1 IgG1 ABs and
isotype-matched nonreactive CTL ABs were injected at
gestational days E13 and E17 (240μg each), and AB-
mediated effects were investigated in the offspring at
660 Volume 86, No. 5
ANNALS of Neurology
different developmental stages (see Fig 1). Monoclonal
human NR1 ABs used in this study showed the character-
istic binding on murine brain sections, for example, to
granular cells in the cerebellum and to NR1 protein in
routine cell-based assays, whereas CTL ABs were non-
reactive on NR1-transfected cells and brain sections.
ELISA quantification in murine serum confirmed that
human IgG were transferred into and enriched in neo-
nates (up to P7 in NR1 AB-treated mice) with declining
levels afterward. Injections starting postpartum proved
transfer of human IgG also via breast milk. Western blot
analyses detected comparable amounts of human total IgG
in the brains of NR1 and CTL AB-treated animals.
NR1-specific human IgG was found in neonatal whole
brain extracts via ELISA only following prenatal NR1 AB
injections with increasing concentrations between P0
and P7.
We next examined whether brain-accumulated NR1
ABs retained the capability of binding the NMDAR.
Extracts of brain-bound IgG from NR1 AB-treated but
not from CTL AB-treated animals were reactive to
NR1-transfected HEK cells at days P0 (see Fig 1J, K) and
P7 (not shown). The anatomical distribution was strik-
ingly different between groups, as confirmed with immu-
nohistochemical colabeling of fetal brain tissue (E19).
Whereas CTL ABs were diffusely distributed in proximity
to CD31-positive blood vessels, NR1 ABs overlapped with
the presynaptic marker VGLUT1 in a characteristic punc-
tate parenchyma pattern not confined to vasculature
(see Fig 1).
Maternal NR1 ABs Reduced NMDAR Density
and Changed Electrophysiological Properties in
Early Postnatal Life
Observed binding of human ABs to NR1 led to the ques-
tion of whether transferred ABs reduce density of
NMDAR in the neonatal brain. Western blots of purified
synaptosomes showed a significantly reduced density in
NR1 AB-treated neonates, indicating profound loss of
synaptic NMDAR, which was absent at P7 (Fig 2). Simi-
larly, brain membrane fractions and total-cell fractions
contained significantly less NR1 protein than in CTL AB-
treated animals at P0, but returned to normal levels at P7.
As a control, NR1 AB-treated animals showed no reduc-
tion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptors (AMPARs; GluR1) in total-cell fractions at
P0. Corresponding histological quantification of NMDAR
clusters colocalizing with synaptic Homer-1 revealed
strong reduction (up to 49.2%) in synaptic NMDAR
cluster densities in the early postnatal brain, which was
less marked at P7. The human monoclonal NR1 AB used
for detection (#007-168) did not compete with the
human treatment AB (#003-102) or the Homer-1
AB. Reduction of synaptic NMDAR was paralleled by
electrophysiological changes in brain slices. NR1 AB-
treated animals at day P0 showed significantly reduced
amplitudes of sEPSCs, which normalized until P7. The
frequency of sEPSCs was not altered.
Increased Mortality and Altered Physiological
Parameters in NR1 AB-Exposed Offspring
NR1 AB-treated neonates displayed significantly reduced
survival rates within the first 3 postnatal days (66.7%)
compared to CTL AB-treated (#mGo53, 93.9%; GFAP,
100%; IVIG, 100%) and untreated (95.2%) offspring
(Fig 3). Survival rates markedly varied in the NR1 group,
ranging from 0 to 100%, whereas they never fell below
60% in controls. As animals did not die later than P3, we
investigated vegetative functions related to acid–base
metabolism early after birth. Blood gas analysis showed a
highly significantly elevated blood pH in NR1 AB-treated
neonates. Surviving animals in the NR1 group gained less
body weight during breastfeeding. The difference persisted
after weaning during adolescence in both female and male
mice and diminished in adulthood (8 weeks). Changes
were not attributable to dysfunctional maternal behavior,
as dams were asymptomatic, and showed normal maternal
care (pup retrieval test35), breastfeeding, and nesting (data
not shown), and the litter size was not different excluding
prepartum death of embryos. Whole brain volumes and
hippocampal volumes were not affected between both
groups at birth using MRI. However, brain volumes were
significantly reduced in the NR1 AB-treated offspring
after 8 weeks and 10 months. The strongest reduction was
detectable in cerebellum, midbrain, and brainstem
(Table 1). Activity recordings revealed significantly higher
baseline activity (+27.8% comparing median over 14 days)
in the home cages of NR1 AB-treated animals during the
dark (active) phase.
Maternal NR1 ABs Delayed Neurodevelopment
in Neonates, Reduced Anxiety Behavior, and
Impaired Prepulse Inhibition in Adult Offspring
We next examined whether the development of early post-
natal reflexes was impaired. Compared to controls, mice
of the NR1 group had significantly reduced abilities for
righting between P5 to P8 (Fig 4). Similarly, development
of the cliff avoidance reflex was significantly impaired, and
the negative geotaxis reflex was significantly delayed
between P4 and P9 in NR1 AB-treated animals. During
adolescence (6–7 weeks), animals of both groups had simi-
lar social preference in the 3-chamber test and equal abili-
ties in spatial learning and memory in the Barnes maze
test. NR1 animals at 9 weeks showed decreased prepulse
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inhibition (PPI; −8.9%) at 69dB only, indicating subtle
changes in sensorimotor gating function that persisted into
adulthood. Likewise, NR1 AB-treated animals spent more
time in and entered more often the open arms of the ele-
vated plus maze, which was not related to faster locomo-
tion, thus indicating lower anxiety. In the home cage,
nests built by either group were similarly complex, and
the naturally expressed behaviors (ie, climbing, drinking,
sleeping) did not quantitatively differ between groups.
Serum Anti-NR1 IgG Reactivity in Mothers of
Children with Psychiatric Disorders
To estimate whether NR1 autoreactivity can also be found
in the serum of human mothers, we compared samples of
120 MCPD versus 105 CTLM. Children from MCPD
had various psychiatric disorders ranging from hyperki-
netic or emotional disorders to depressive episodes and
pervasive developmental disorders; the pregnancies were
4 to 20 years before serum sampling (Table 2). Using our
FIGURE 2: Legend on next page.
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flow cytometry–based approach to objectively measure the
continuous spectrum of NR1 IgG autoreactivity, titers
were slightly higher in MCPD samples compared to
CTLM (p = 0.038; Fig 5). Dose-titration curves with
human monoclonal NR1 ABs and isotype-matched non-
reactive CTL ABs revealed high sensitivity with flow cyto-
metry even at a concentration of 1ng/ml. No specific
psychiatric disorder was favored in children of MCPD
with the highest titers. We next determined whether the
enrichment of ABs in the fetal circulation can lead to
clearly detectable IgG titers in the pups despite negative
AB results in dams using a routine ELISA. Stepwise titra-
tion of injected human IgG resulted in this “ser-
opositivity/seronegativity” discrepancy in the 6.6μg group,
suggesting that pregnant women testing “negative” for
NR1 ABs in clinical routine assays may not exclude fetal
enrichment.
Discussion
Human IgG NR1 ABs were detected with cell-based assays
in 1% of asymptomatic controls in previous studies,11,12 cre-
ating a considerable subgroup of pregnant women at risk of
transferring this anti-neuronal AB to the fetus. The preva-
lence of low-titer NR1 ABs might even be higher, as routine
cell-based assays work with clear cutoff values for detection
of patients with suspected NMDAR encephalitis. To model
the underlying risk in mice, we administered human recom-
binant NR1 ABs into pregnant animals. The offspring had
reduced densities of synaptic NMDAR, increased mortality,
altered physiological functions, and impaired neuro-
development. Most importantly, mild behavioral changes
persisted into adulthood and were accompanied by signifi-
cantly reduced brain volumes, indicating the potential of
lifelong neuropsychiatric consequences from transient expo-
sure to maternal NR1 ABs during pregnancy. Given the
increased mortality in NR1 AB-treated offspring, surviving
animals might have been more mildly affected, resulting in
underestimation of the AB effect.
In a translational approach, data from the present
study indicate that healthy MCPD may have higher serum
NR1 IgG reactivity compared to CTLM. The effect was
only subtle, potentially weakened due to spontaneous fad-
ing of NR1 AB titers over time (as known from autoim-
mune encephalitis) given the long interval (4–20 years)
between pregnancy and AB testing. We compared the
continuous spectrum of NR1 autoreactivity rather than
categorizing only extremely high titers (“seropositive,”
which may indicate NMDAR encephalitis) as MCPD
were asymptomatic (see Fig 5A). Interestingly, even
below-threshold maternal serum titers of NR1 ABs may
result in fetal IgG enrichment (see Fig 5C). Similar to
human placental FcRn, IgG is actively transported into
the fetal murine circulation via the FcRn in the yolk sac.36
In contrast to humans, maternal IgG reaches the neonatal
circulation in mice also via secretion into breast milk.37 In
both species, the fetal BBB is not fully developed,38 all-
owing interference of ABs with fetal development while
not crossing the intact maternal BBB. Binding to
NMDAR might further retain and increase the ABs in the
fetal brain, as in an injection model using animals with
disrupted BBB.39 Thus, high levels of ABs might not be
required to distinguish MCPD from CTLM. In asymp-
tomatic human mothers with low or even subthreshold
FIGURE 2: Quantification of synaptic N-methyl-D-aspartate receptor density and characterization of electrophysiological
properties in antibody (AB)-treated neonates. (A–C) Representative Western blots (cropped) of synaptosomal (A), membrane (B),
and total-cell fractions (C) prepared from neonatal brains at postnatal day (P) 0 showed NR1 protein reduction, as compared
with the respective reference protein. Quantification showed significant NR1 protein reduction in all 3 fractions (n = 8 from 3–5
different litters; mean  standard deviation [SD], unpaired t test, p = 0.0063 [A], p = 0.0365 [B], p = 0.0005 [C]). (D) Control (CTL)
blots showed no reduction of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (GluR1) protein at P0 in the total-
cell fraction. (E, F, H, I) NR1 protein reduction was also observed when comparing immunohistochemistry of NR1-positive
clusters (E, H) with expression of the synaptic protein Homer-1 (F, I). (G, J) The overlays demonstrated much less colocalization in
NR1 AB-treated animals (J) compared to controls (G). (K) Quantification of the percentage of NR1+ clusters of all Homer-1+
clusters showed strong reduction at P0 (n = 5 from 5 different litters, mean  SD, unpaired t test, p < 0.0001), which was less
pronounced at P7 (n = 5 from 4–5 different litters, mean  SD, unpaired t test, p = 0.0102). For cluster quantification in E–K, AB
treatment was done with a monoclonal human NR1 AB (#003-102) different from the human detection AB (#007-168). This was
possible as both ABs did not compete for the identical epitope (L–P), exemplarily shown for #003-102 alone (L, signal intensity
measured in the hippocampal stratum radiatum [mean of the white circles] minus background fluorescence [turquoise circle]),
#003-102 competing with 100μg/ml #003-102 (M) or 100μg/ml #007-168 (N, insert shows hippocampal binding of the Homer-1
AB). (P) Quantification of the respective dose curves showed that each monoclonal NR1 AB was only displaced by itself but not
by the other NR1 or a Homer-1 AB (n = 4 independent experiments). (Q, R) Representative recordings of spontaneous excitatory
postsynaptic currents (sEPSCs) in neonatal brain slices at P0 (Q) and P7 (R). (S) Quantification revealed marked reduction of
sEPSC amplitudes at P0 (n = 16 [CTL] and n = 12 [NR1] cells from 5 neonates from 5 different litters, mean  SD, unpaired t test,
p = 0.0176), which normalized until P7 (n = 15 [CTL] and n = 12 [NR1] cells from 6 neonates from 6 different litters, p = 0.088).
(T) sEPSC frequencies were not affected (mean  SD, unpaired t test, p = 0.0688 [P0], p = 0.994 [P7]). *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. hum = human; n.s. = not significant.
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serum NR1 AB titers, fetal NR1 IgG might still accumu-
late to a degree sufficient for permanent damage to the
developing brain. Also, other factors could facilitate
maternofetal AB transfer and induce neuropsychiatric dis-
ease, such as inflammation, genetic risk loci, placental
microstructure, or psychosocial stress ("second hits").
Support for our model also comes from previous
murine models of maternal anti-neuronal ABs affecting fetal
development with long-term defects in the offspring.6–9 Ges-
tational transfer of IgG from mothers of children with ASD
into mice resulted in reduced sociability and increased anxi-
ety.7,8 Active immunization against the NMDAR-NR2A/-
FIGURE 3: Legend on next page.
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NR2B (GluN2A/2B) subunits in pregnant dams led to
death of female fetuses, altered histological properties, and
long-lasting cognitive defects in male offspring.6 In another
study, human recombinant Caspr2 ABs were passively trans-
ferred into mice, resulting in abnormal cortical development
in male offspring with decreased dendritic complexity and
abnormal behavior.9 Similarly, Caspr2 AB-containing mater-
nal IgG fractions led to marked social interaction deficits in
the offspring, disturbances in layer formation in somatosen-
sory cortex, and increased microglial activation.10
Synaptic NMDAR activity is involved in different
stages of fetal and neonatal brain development, crucial for
FIGURE 3: Mortality and physiological parameters of control (CTL) and NR1 antibody (AB)-treated offspring. (A) Kaplan–Meier
analysis of neonate survival showed significantly increased mortality in NR1 AB-treated animals (log-rank test, corrected with
Bonferroni correction for K = 5, adjusted p = 0.025 [NR1 vs CTL]) compared to all 4 control groups. (B) Survival rates of
untreated, CTL, glial fibrillary acidic protein (GFAP), intravenous immunoglobulin (IVIG), and NR1 AB-treated neonates at
postnatal day (P) 3 with different doses (untreated: n = 3 litters; 480μg: n = 13 [CTL], n = 17 [NR1], n = 3 [GFAP], n = 3 [IVIG];
960μg: n = 3 [CTL], n = 3 [NR1]). (C) Blood pH of untreated, CTL, and NR1 AB-treated neonates at P0 showed significantly
elevated pH in the NR1 group (untreated: n = 26 from 3 litters; CTL ABs: n = 17 from 3 litters; NR1 ABs: n = 33 from 4 litters;
mean  standard deviation [SD], 1-way analysis of variance [ANOVA], post hoc Tukey multiple comparison test, untreated vs CTL
ABs: p = 0.1685; untreated vs NR1 ABs: p = 0.0488; CTL vs NR1 ABs: p = 0.0002). (D–F) Development of body weight of
breastfed neonates (D), females (E), and males (F) after weaning (mean  SD, repeated measures ANOVA, Sidak multiple
comparison test, p < 0.0001 for NR1 vs all 3 control groups). (G) Litter size did not differ between all treatment groups (n = 17
[CTL], n = 20 [NR1], n = 3 [GFAP], n = 3 [IVIG]). (H) Representative brain magnetic resonance imaging (MRI) of CTL and NR1 AB-
treated neonates (hippocampal regions highlighted). (I, J) MRI-based quantification showed similar volumes at P0 in both groups
for hippocampus (I; n = 16, mean  SD, unpaired t test, p = 0.3158) and total brain (J [left]; n = 16, mean  SD, unpaired t test,
p = 0.176). With long follow-up, total brain volumes of 8-week-old (J [middle]; CTL, n = 15; NR1, n = 15; mean  SD, unpaired
t test, p = 0.0001) and 10-month-old mice (J [right]; CTL, n = 16; NR1, n = 14; mean  SD, unpaired t test, p = 0.0005) showed
highly significant differences in total brain volumes. (K) Typical activity (mean of distance traveled) in home cages during 3 dark
(black bars) and 4 light phases of adult offspring. (L) In dark phases, home cage activity (boxplots of distance traveled) of NR1
(n = 10) compared to CTL AB-treated animals (n = 11) was consistently higher during 14 days and in total (boxplots: median,
25th–75th quartile, minimum–maximum; Wilcoxon test of dark phase over all days, test score = 179, p = 0.0049). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001. n.s. = not significant.
TABLE 1. Comparison of Absolute Volumes of Different Brain Regions after 8 Weeks and 10 Months
Region
8 Weeks 10 Months
CTL, n = 15,
Mean  SD
NR1, n = 15,
Mean  SD p Sign.
CTL, n = 16,
Mean  SD
NR1, n = 14,
Mean  SD p Sign.
Cerebellum 45.32  0.87 40.97  1.72 1.79E-9 a 48.61  1.49 44.61  1.23 1.23E-8 a
Midbrain 22.74  0.58 21.48  0.65 5.90E-6 a 24.25  0.96 22.92  0.50 7.00E-5 a
Brainstem 86.39  1.83 80.73  2.73 3.00E-7 a 93.05  3.11 88.47  2.32 0.0001 a
Pallidum 8.02  0.31 7.50  0.36 0.0002 b 9.27  0.42 8.94  0.22 0.0133
Hypothalamus 12.01  0.71 11.20  0.47 0.0004 b 13.53  0.85 12.90  0.60 0.0299
Cerebral
cortex
173.83  3.61 166.45  2.75 8.31E-7 a 190.90  5.36 187.26  3.68 0.0414
Striatum 39.99  1.29 34.54  1.21 1.03E-5 a 41.52  1.42 40.69  0.96 0.0738
Hippocampus 35.59  0.98 33.64  1.06 1.52E-5 a 39.26  1.56 38.58  1.83 0.2780
Thalamus 19.44  0.51 18.40  0.53 5.49E-6 a 21.71  0.71 21.38  1.02 0.3027
Amygdala 0.96  0.05 0.92  0.03 0.0041 c 1.07  0.05 1.06  0.03 0.6579
Probability values were not adjusted. Values are expressed in mm3. Changes in total brain volumes were treatment-specific (8 weeks: p < 0.0001;
10 months: p = 0.0015), but not sex-specific (8 weeks: p = 0.284; 10 months: p = 0.677; 2-way analysis of variance of treatment versus sex
interaction).
ap < 0.0001; bp < 0.001; cp < 0.01.
CTL = control; SD = standard deviation; Sign. = significance level.
November 2019 665
Jurek et al: maternal NMDAR antibodies
circuit development and map formation, and deletion of
the NR1 subunit is lethal.40 In accordance with other
in vitro and in vivo studies,14,15 we here showed removal
of NMDAR from the surface. This reduction was accom-
panied by decreased amplitudes of AMPAR-mediated
sEPSCs, only present in young neonates (P0). Despite the
FIGURE 4: Legend on next page.
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lack of data for direct NMDAR function, affected
AMPAR-mediated signaling was treatment-specific, and
likely resulted from disrupted NMDAR-mediated inser-
tion of AMPAR,20 normalizing at P7. The seeming dis-
crepancy between increasing postpartum AB levels in
serum and brain versus decreasing effects on NMDAR
density and function indicate an early developmental win-
dow of high susceptibility. At this time, NMDAR are pri-
marily responsible for glutamatergic transmission but are
expressed at low levels. Thus, they cannot compensate the
NR1 AB-mediated detrimental effect, whereas this is likely
possible when NMDAR expression increases considerably
later on.
Defects in our NR1 AB-treated animals likely were
related to NMDAR dysfunction, as they resembled
genetic and autoimmune models. For example, affected
neonates had >27% increased mortality in the first postna-
tal days and markedly increased blood pH, a clinical
parameter of acid-base metabolism and respiratory func-
tion. Loss-of-function mutations in the NR1 gene were
lethal,22 and NR1 knockout mice died within 8 to
15 hours after birth due to respiratory failure.41 Small
neonatal blood volumes prevented additional measure-
ment of pCO2, pO2, or HCO3 levels from further deter-
mining respiratory, neuromuscular, and metabolic
contributions. Genetic models usually showed a more
FIGURE 4: Neurodevelopmental and behavioral impairment from postnatal to adult mice in NR1 antibody (AB)-treated
offspring. (A–C) Delayed development of the righting reflex (A), cliff avoidance (B), and negative geotaxis (C) in NR1 AB-treated
neonates compared to controls (3–6 litters, n = 17 [control (CTL)], n = 14 [NR1], n = 15 [glial fibrillary acidic protein (GFAP)],
n = 15 [intravenous immunoglobulin (IVIG)], points symbolize % of population showing the respective reflex, 1-sided Fisher exact
test for each day; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, NR1 vs CTL). (D) Normal social preference of adolescent
mice from both treatment groups (n = 23 [CTL], n = 16 [NR1] from 5 litters, median  95% confidence interval [CI], Mann–
Whitney U test, p = 0.4115). (E) Memory recall in the Barnes maze was not impaired 1 and 7 days after learning (n = 9 [CTL],
n = 6 [NR1] from 2 litters, median  95% CI, Kruskal-Wallis-test, p = 0.1322). (F) Prepulse inhibition (PPI) determined by startle
reaction showed impaired sensorimotor gating in NR1 AB-treated mice (n = 20 [CTL], n = 21 [NR1] from 5 litters, median  95%
CI, Kruskal–Wallis test with Dunn post hoc test: PP69dB, p = 0.0263; PP73dB, p = 0.7964; PP81dB, p = 0.9650). (G, G0) Anxiety
was lower in the NR1 group as displayed by longer duration in open arms (G, n = 20 [CTL], n = 16 [NR1] from 4 litters,
median  95% CI, Mann–Whitney U test, p = 0.0494) and increased number of entries into open arms of the elevated plus maze
(G0, p = 0.0139). (G00) Velocity was not affected by AB treatment (p = 0.3475). (H) Nest construction was normal as measured by
the weight of unused nest material (n = 20 [CTL], n = 16 [NR1] from 4 litters, median  95% CI, Kruskal–Wallis test, p = 0.0718).
(I–K) Individual behavior was recorded with a HomeCageScan system for each mouse and did not show significant differences in
any recorded behavior, including climbing behavior (I; CTL, n = 9; NR1, n = 6, mean  SD [dotted lines], repeated measures
analysis of variance; between-subject factor p = 0.9957), consumption (eating + drinking) behavior (J; between-subject factor
p = 0.1857), and sleeping behavior (K; p = 0.9628). n.s. = not significant; N = white noise; P = pulse; PP = prepulse.
FIGURE 5: Serum NR1 autoreactivity in mothers of children with psychiatric disorders (MCPD) compared to healthy control
mothers of unaffected children (CTLM). (A) Antibody (AB) reactivity (median fluorescence intensity [ΔMFI]) of sera against
NR1-expressing HEK cells was increased in MCPD (n = 120) versus CTLM (n = 105, mean  SD; unpaired t test, *p = 0.038).
Serum of N-methyl-D-aspartate receptor encephalitis (NMDARE) patients served as positive controls (right; n = 2). (B) The flow
cytometry assay showed high sensitivity even in the low ng/ml range as validated with monoclonal human NR1 versus control
(CTL) ABs. (C) Increasing doses of maternally injected human immunoglobulins consistently resulted in murine fetal AB
enrichment. A given AB dose (here single maternal injection of 6.6μg human IgG) can lead to clearly detectable titers in pups
(circles), whereas it remains under the detection threshold (blue line, <0.5μg/ml in this routine enzyme-linked immunosorbent
assay) in the mother (rectangles). IVIG = intravenous immunoglobulin.
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severe phenotype, whereas NR1 AB-treated animals per-
formed well in paradigms of social behavior, spatial learn-
ing, and nest construction, which is likely related to
normalization of NMDAR function with fading AB titers.
Clinical experience with pregnant NMDAR encephalitis
patients further supports the pathogenic effects of in utero
exposure to human NR1 ABs42–46 and even demonstrated
4-fold higher titers in a newborn.45 Obvious neonatal
developmental impairment was seen in approximately half
of the babies.47 The lack of follow-ups prevented any con-
clusion on potential further deficits with later onset.
Midgestational sera from a Danish biobank revealed sig-
nificantly higher frequencies of NMDAR ABs (29%) in
mothers with schizophrenia spectrum disorders (SSD)
whose children were diagnosed with mental retardation
and disorders of psychological development, compared to
mothers with SSD and unaffected children.48 Such differ-
ence was not seen in mothers without SSD.48
Offspring from our murine study displayed behav-
ioral signs resembling several models of neuropsychiatric
developmental disorders. For example, surviving animals
showed impaired neurodevelopment, lower bodyweight,
and delayed neonatal sensory–motor reflexes, similar to
gestational transfer models of ASD7 and learning disabil-
ities related to anti-NR2A/B ABs.6 In humans, motor
delays are observed in 51% of individuals with ASD.49
Moreover, behavioral changes manifesting later in life in
NR1 AB-treated animals included elevated activity,
decreased anxiety behavior in the elevated plus maze, and
partially reduced PPI. Hyperlocomotion is a hallmark of
several neuropsychiatric disorders, such as attention-defi-
cit/hyperactivity disorder (ADHD), bipolar disorders, and
schizophrenia, in both humans and rodent models50 and
in mice with reduced NMDAR expression.51,52 Reduction
of anxiety was equally well documented in ADHD
models.53 Finally, NR1 AB-treated animals were similar
to animals with reduced NMDAR expression by decreased
PPI, reflecting impaired sensorimotor gating and precon-
scious attention.50–52 PPI is reduced not only in schizo-
phrenia, but also in psychotic bipolar disorder and
ADHD.54
The findings collectively suggest that diaplacentally
transferred NR1 ABs are not linked to a single (NMDAR
encephalitis-like) disorder, but could potentially contrib-
ute to a broader spectrum of behavioral abnormalities
found in ADHD, ASD, bipolar disorders, schizophrenia,
or learning disabilities. In line with this hypothesis, mater-
nal NR1 ABs induced long-lasting neuropathological
effects in the offspring, with reduced volumes of several
brain areas in old mice. The mechanisms behind the del-
ayed development of pathological changes require further
TABLE 2. Cohort Characteristics of Matched
Mothers of Children with Psychiatric Disorders
(n = 120, Mean Age = 42.3  7.8 Years) and
Healthy Control Mothers of Unaffected
Children (n = 105, Mean Age = 43.6  9.7 Years)
ICD-10
Disorder
Classification Cases M F


















F6 Disorders of adult
personality and behavior
2 0 2





























Diagnoses of psychiatric disorders were coded according to the Ger-
man modification of the ICD-10 as provided within health insur-
ance data.
F = female; ICD-10 = International Classification of Diseases and
Related Health Problems, 10th Revision; M = male.
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research and may include dysfunctional formation of corti-
cal layers or NR1-mediated effects on progenitor cells.55
Thus, gestational NR1 AB exposure may primarily be seen
as a neurodevelopmental congenital brain disorder that is
potentially amenable to immunotherapy, thus clearly
deserving detailed analyses in future animal and prospec-
tive human studies with long follow-up. These should
determine the kinetics of AB titers over time in mothers
and neonates, presence of clinical neuropsychiatric symp-
toms and developmental delays, and contribution of addi-
tional risk factors.
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